SPXU vs XBI
ProShares UltraPro Short S&P500 vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.90% for SPXU.
- • SPXU pays a higher dividend yield (6.87%).
Side-by-side metrics
| Metric | SPXU | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.90% | 0.35% |
Dividend yield Trailing 12-month yield. | 6.87% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $562M | $8.30B |
YTD return | -19.75% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | -2.75 | 1.09 |
P/E ratio | — | — |
Last price | $39.97 | $133.66 |
Inception | — | — |
Issuer | ProShares | State Street |
SPXU top holdings
| IQMM | ProShares GENIUS Money Market ETF | 68.61% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About SPXU
SPXU (ProShares UltraPro Short S&P500) is 3x inverse daily performance of the S&P 500. Managed by ProShares, the fund carries $562M in assets under management, an expense ratio of 0.90%, a dividend yield of 6.87%. Its largest holding is ProShares GENIUS Money Market ETF (IQMM), which represents 68.6% of the portfolio.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.